This is not financial advice. This thesis is exclusively based on technical analysis without catalyst. Bullish trend expected to continue and hit new highs as long as volume is high. Stop loss set at closest support.
Why get subbed to to me on Tradingview?
-TOP author on TradingView
-15+ years experience in markets
-Professional chart break downs
-Supply/Demand Zones
-TD9 counts / combo review
-Key S/R levels
-No junk on my charts
-Frequent updates
-Covering FX/crypto/US stocks
-24/7 uptime so constant updates
ARDX D1::BEST level to BUY 100% gains (SWING)(STOCKS)
IMPORTANT...
This is not financial advise
you do what is make you feeling comfort
ARDX will easy hit
Short Term :
TG1 $7
Long term :
TG2 $7.57
TG3 $8.05
if you like me advise follow me
thanks for your support
This is not financial advise
you do what is make you feeling comfort
ARDX will easy hit
Short Term :
T1 $7
Long term :
T2 $7.57
T3 $8.05
if you like me advise follow me
thanks for your support
This is not financial advise
you do what is make you feeling comfort
ARDX will easy hit
Short Term :
TG1 $7
Long term :
TG2 $7.57
TG3 $8.05
if you like me advise follow me
thanks for your support
ARDX: Ardelyx
2020-06-15 08:00:00
Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis
After breaking to higher ground a week ago on enormous volume, shares of ARDELYX INC - NASDAQ: ARDX find themselves in constructive consolidation mode digesting the recent run on lower volume as we can observe from the Daily chart above.
With the stock trading well above its 20/50 and 200 DMA's on the Daily timeframe, the short-term technical posture of ARDX ...
05:13 Piper still sees 'substantial upside' in Ardelyx despite last week's rally
Piper Jaffray analyst Christopher Raymond says he still expects "substantial upside" in shares of Ardelyx even after last week's 43% move. While Amplify's more "real world" representation assuaged the key investor concern around tenapanor's adverse event-related discontinuations,...
Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipation. Its product portfolio includes tenapanor, which is an experimental...
Large insto bets have been placed at this $4 level. My feeling is this price level will hold, in which case it is only a matter of time before it breaks out of this descending chanel. An impulsive move up is then likely.
ARDX forming a nice fallen angel base, with higher lows. Twinges moneyflow showing strong divergence.
We think it has good upside potential.
* Trade Criteria *
Date First Found- August 22, 2017
Pattern/Why- Fallen angel pattern
Entry Target Criteria- Break of $5.53
Exit Target Criteria- $5.97
Stop Loss Criteria- $5.17
Please check back for Trade updates....
